Cowen And Company, LLC Arbutus Biopharma Corp Transaction History

Cowen And Company, LLC

$3.91 Billion
Q2 2024

A detailed history of Cowen And Company, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Cowen And Company, LLC holds 20,000 shares of ABUS stock, worth $76,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,000

Previous 50,000 60.0%

Holding current value

$76,600

Previous $129,000 52.71%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$2.52 - $3.63 $75,600 - $108,900	-30,000 Reduced 60.0%	20,000 $61,000
Q4 2023 Feb 08, 2024	BUY	$1.69 - $2.54 $84,500 - $127,000	50,000 New	50,000 $125,000
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $775,058 - $1.15 Million	-249,215 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$2.65 - $4.62 $572,670 - $998,391	-216,102 Reduced 46.44%	249,215 $1.07 Million
Q2 2021 Aug 13, 2021	SELL	$2.5 - $3.51 $53,500 - $75,114	-21,400 Reduced 4.4%	465,317 $1.41 Million
Q1 2021 May 04, 2021	BUY	$3.14 - $4.84 $67,196 - $103,576	21,400 Added 4.6%	486,717 $1.62 Million
Q4 2020 Feb 08, 2021	SELL	$2.76 - $4.97 $20,236 - $36,440	-7,332 Reduced 1.55%	465,317 $1.65 Million
Q3 2020 Nov 03, 2020	SELL	$1.75 - $6.2 $6.75 Million - $23.9 Million	-3,858,371 Reduced 89.09%	472,649 $1.48 Million
Q1 2020 May 11, 2020	BUY	$1.01 - $3.42 $3.44 Million - $11.6 Million	3,404,820 Added 367.61%	4,331,020 $4.37 Million
Q4 2019 Feb 11, 2020	BUY	$0.87 - $2.89 $805,794 - $2.68 Million	926,200 New	926,200 $2.58 Million

Others Institutions Holding ABUS

# of Institutions

137

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $574M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.

Account

Cowen And Company, LLC Arbutus Biopharma Corp Transaction History